Stay updated with breaking news from Nasdaq Cbay. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Free Report) General Counsel Paul T. Quinlan sold 5,000 shares of the business’s stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $11.91, for a total transaction of $59,550.00. The transaction was disclosed in a document filed with the Securities & […]
CymaBay Therapeutics (NASDAQ:CBAY – Free Report) had its price target raised by BTIG Research from $18.00 to $22.00 in a research report sent to investors on Friday, MarketBeat reports. BTIG Research currently has a buy rating on the biopharmaceutical company’s stock. Several other equities analysts have also recently issued reports on CBAY. Guggenheim initiated coverage […]
HC Wainwright reiterated their buy rating on shares of CymaBay Therapeutics (NASDAQ:CBAY – Free Report) in a research report report published on Thursday, Benzinga reports. The firm currently has a $19.00 target price on the biopharmaceutical company’s stock. Other research analysts also recently issued reports about the stock. StockNews.com downgraded shares of CymaBay Therapeutics from […]
CymaBay Therapeutics (NASDAQ:CBAY – Get Free Report) had its price target increased by HC Wainwright from $19.00 to $21.00 in a research note issued on Monday, FlyOnTheWall reports. HC Wainwright’s target price indicates a potential upside of 66.53% from the company’s previous close. Several other equities research analysts have also weighed in on the company. […]
Stock analysts at Guggenheim assumed coverage on shares of CymaBay Therapeutics (NASDAQ:CBAY – Get Free Report) in a research report issued to clients and investors on Friday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $20.00 price target on the biopharmaceutical company’s stock. Guggenheim’s price objective would suggest a potential upside of […]